Onset of Retinal Pigment Epithelium Atrophy Subsequent to Anti-VEGF Therapy in Patients with Neovascular Age-Related Macular Degeneration.

Autor: Sitnilska V; Department of Ophthalmology, University Hospital of Cologne, Cologne, Germany., Altay L; Department of Ophthalmology, University Hospital of Cologne, Cologne, Germany, lebriz.altay@uk-koeln.de., Enders P; Department of Ophthalmology, University Hospital of Cologne, Cologne, Germany., Hermann M; Department of Ophthalmology, University Hospital of Cologne, Cologne, Germany., Muether PS; Department of Ophthalmology, University Hospital of Cologne, Cologne, Germany., Fauser S; Department of Ophthalmology, University Hospital of Cologne, Cologne, Germany.; F. Hoffmann-La Roche AG, Basel, Switzerland.
Jazyk: angličtina
Zdroj: Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde [Ophthalmologica] 2019; Vol. 241 (3), pp. 154-160. Date of Electronic Publication: 2018 Oct 10.
DOI: 10.1159/000492924
Abstrakt: Purpose: The aim of this study was to evaluate risk factors for the development of retinal pigment epithelium (RPE) atrophy in patients with neovascular age-related macular degeneration (nAMD).
Procedures: This post hoc analysis of the prospective RESPONSE study includes 52 therapy-naive nAMD patients without baseline RPE atrophy, who were treated with ≥9 anti-vascular endothelial growth factor (VEGF) injections for ≥3 years. RPE atrophy was assessed via multimodal imaging. Baseline aqueous VEGF and serum complement levels (C3d/C3) were measured. Risk factors for atrophy development were evaluated via logistic regression analysis.
Results: Atrophy onset was significantly associated with the duration of nAMD (mean 5.34 years; odds ratio = 1.83, p = 0.012). Anti-VEGF injection number, age, C3d/C3 ratio, baseline intraocular VEGF, or delay to the first treatment had no influence on RPE atrophy.
Conclusions: The duration of treatment-requiring nAMD was identified as primary risk factor for the onset of concomitant RPE atrophy after commencing therapy. Targeting concomitant atrophy in nAMD patients might improve the long-term prognosis of the disease.
(© 2018 S. Karger AG, Basel.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje